Squarepoint Ops LLC Decreases Position in MaxCyte, Inc. (NASDAQ:MXCT)

Squarepoint Ops LLC decreased its holdings in shares of MaxCyte, Inc. (NASDAQ:MXCT) by 75.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 34,643 shares of the company’s stock after selling 109,174 shares during the quarter. Squarepoint Ops LLC’s holdings in MaxCyte were worth $144,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in MXCT. Two Sigma Advisers LP purchased a new stake in MaxCyte in the fourth quarter valued at approximately $74,000. ProShare Advisors LLC lifted its stake in MaxCyte by 32.6% in the fourth quarter. ProShare Advisors LLC now owns 34,462 shares of the company’s stock valued at $143,000 after buying an additional 8,481 shares during the last quarter. Mudita Advisors LLP lifted its stake in MaxCyte by 2.2% in the fourth quarter. Mudita Advisors LLP now owns 3,223,407 shares of the company’s stock valued at $13,409,000 after buying an additional 69,966 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in MaxCyte by 4.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,929 shares of the company’s stock valued at $249,000 after buying an additional 2,584 shares during the last quarter. Finally, Graham Capital Management L.P. purchased a new stake in MaxCyte in the fourth quarter valued at approximately $96,000. Hedge funds and other institutional investors own 68.81% of the company’s stock.

MaxCyte Price Performance

MaxCyte stock opened at $2.15 on Monday. MaxCyte, Inc. has a 12 month low of $2.10 and a 12 month high of $5.26. The business has a 50 day simple moving average of $2.48 and a 200-day simple moving average of $3.44. The stock has a market capitalization of $228.59 million, a PE ratio of -6.32 and a beta of 1.27.

MaxCyte (NASDAQ:MXCT) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. The business had revenue of $10.39 million during the quarter, compared to analysts’ expectations of $9.05 million. As a group, equities research analysts anticipate that MaxCyte, Inc. will post -0.42 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on MXCT shares. BTIG Research set a $6.00 price objective on MaxCyte and gave the company a “buy” rating in a research note on Wednesday, March 12th. Wall Street Zen upgraded MaxCyte from a “sell” rating to a “hold” rating in a research note on Sunday. Finally, Stifel Nicolaus reduced their price objective on MaxCyte from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday, March 12th.

MaxCyte Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.